Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Cetuximab/rituximab/trastuzumab emtansine

Type-I hypersensitivity reaction in the form of anaphylaxis: 6 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lopes JB, et al. Management of patients with suspected hypersensitivity to monoclonal antibodies: Experience of a service. [Portuguese]. Revista Portuguesa de Imunoalergologia 30: 101-109, No. 2, Jun 2022. Available from: URL: https://rpia.spaic.pt/arquivo [Portuguese; summarised from a translation] Lopes JB, et al. Management of patients with suspected hypersensitivity to monoclonal antibodies: Experience of a service. [Portuguese]. Revista Portuguesa de Imunoalergologia 30: 101-109, No. 2, Jun 2022. Available from: URL: https://​rpia.​spaic.​pt/​arquivo [Portuguese; summarised from a translation]
Metadaten
Titel
Cetuximab/rituximab/trastuzumab emtansine
Type-I hypersensitivity reaction in the form of anaphylaxis: 6 case reports
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30528-1

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Bupivacaine

Case report

Valproic-acid